ESPERANZA: External Control Arm Study for T-DXd for Patients with HER2 IHC3+ Solid Tumors

Trial Identifier: D967VR00001
Sponsor: AstraZeneca
Collaborator:
Daiichi Sankyo
IQVIA
Start Date: June 2025
Primary Completion Date: November 2025
Study Completion Date: November 2025
Condition: Liver Cancer; Cancer - Other; Colorectal Cancer; Endometriosis; Lung Cancer; Ovarian Cancer; Pancreatic Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Austria, NA Vienna, NA, Austria, NA
Belgium, NA Liege, NA, Belgium, NA
Canada, NA London, Ontario, NA, Canada, N6A 5A5
Czechia, NA Olomouc, NA, Czechia, NA
Denmark, NA Copenhagen, NA, Denmark, NA
France, NA Caen, NA, France, NA
France, NA Lille, NA, France, NA
France, NA Marseille, NA, France, NA
France, NA Nice, NA, France, NA
France, NA Paris, NA, France, NA
France, NA Saint-Herblain, NA, France, NA
Germany, NA Berlin, NA, Germany, NA
Germany, NA Frankfurt, NA, Germany, NA
Germany, NA Heidelberg, NA, Germany, NA
Germany, NA W rzburg, NA, Germany, NA
Italy, NA Meldola, NA, Italy, NA
Italy, NA Rome, NA, Italy, NA
Portugal, NA Porto, NA, Portugal, NA
Spain, NA Barcelona, NA, Spain, NA
Spain, NA Madrid, NA, Spain, NA
Spain, NA Pamplona, NA, Spain, NA
Spain, NA Valencia, NA, Spain, NA
UK, NA Leeds, NA, UK, NA
UK, NA London, NA, UK, NA
USA, South Carolina Spartanburg, South Carolina, USA, 29303